GLPwatch
In-patient Study in Patients With Type 2 Diabetes Mellitus
NCT00259896 · Completed
Last updated 2026-05-28This clinical trial is testing how a medication affects people with type 2 diabetes over a 7-day hospital stay.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 30 people
Who can join Ages 18–66 · all sexes Healthy volunteers accepted.
Timeline Started 2005-10
What this study is testing ClinicalTrials.gov NCT00259896 ↗
Description as written by the study sponsor.
This study is a placebo-controlled study in both healthy normal subjects and patients with Type 2 Diabetes Mellitus to assess the levels of exenatide in the bloodstream when it is given for 7 days, and to assess the impact this medication has on various substances in the blood. Assessments include repeat blood sampling and monitoring of any side effects.
Treatments tested
- exenatide Drug
| Main thing measured | Pharmacodynamic measurements during 7 days of dosing. |
|---|---|
| Sponsor | GlaxoSmithKline |
| Conditions studied | Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2 |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00259896 ↗